Pharsight

Revlimid patents expiration

REVLIMID's oppositions filed in EPO
REVLIMID IPR and PTAB Proceedings
Can you believe REVLIMID received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8288415 BRISTOL MYERS SQUIBB Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione
Jul, 2016

(7 years ago)

US5635517 BRISTOL MYERS SQUIBB Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines
Oct, 2019

(4 years ago)

US7855217 BRISTOL MYERS SQUIBB Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
Nov, 2024

(5 months from now)

US7465800 BRISTOL MYERS SQUIBB Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
Apr, 2027

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6281230 BRISTOL MYERS SQUIBB Isoindolines, method of use, and pharmaceutical compositions
Jul, 2016

(7 years ago)

US6555554 BRISTOL MYERS SQUIBB Isoindolines, method of use, and pharmaceutical compositions
Jul, 2016

(7 years ago)

US8288415 BRISTOL MYERS SQUIBB Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione
Jul, 2016

(7 years ago)

US7119106 BRISTOL MYERS SQUIBB Pharmaceutical compositions of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Jul, 2016

(7 years ago)

US8589188 BRISTOL MYERS SQUIBB Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
Aug, 2018

(5 years ago)

US6908432 BRISTOL MYERS SQUIBB Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
Aug, 2018

(5 years ago)

US6045501 BRISTOL MYERS SQUIBB Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
Aug, 2018

(5 years ago)

US8204763 BRISTOL MYERS SQUIBB Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
Aug, 2018

(5 years ago)

US6561976 BRISTOL MYERS SQUIBB Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
Aug, 2018

(5 years ago)

US5635517 BRISTOL MYERS SQUIBB Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines
Oct, 2019

(4 years ago)

US6561977 BRISTOL MYERS SQUIBB Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
Oct, 2020

(3 years ago)

US6315720 BRISTOL MYERS SQUIBB Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
Oct, 2020

(3 years ago)

US8315886 BRISTOL MYERS SQUIBB Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
Oct, 2020

(3 years ago)

US6755784 BRISTOL MYERS SQUIBB Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
Oct, 2020

(3 years ago)

US8626531 BRISTOL MYERS SQUIBB Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
Oct, 2020

(3 years ago)

US8404717 BRISTOL MYERS SQUIBB Methods of treating myelodysplastic syndromes using lenalidomide
Apr, 2023

(1 year, 2 months ago)

US7189740 BRISTOL MYERS SQUIBB Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
Apr, 2023

(1 year, 2 months ago)

US9056120 BRISTOL MYERS SQUIBB Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
Apr, 2023

(1 year, 2 months ago)

US9101622 BRISTOL MYERS SQUIBB Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone
May, 2023

(1 year, 1 month ago)

US9101621 BRISTOL MYERS SQUIBB Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
May, 2023

(1 year, 1 month ago)

US8648095 BRISTOL MYERS SQUIBB Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor
May, 2023

(1 year, 1 month ago)

US8530498 BRISTOL MYERS SQUIBB Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione
May, 2023

(1 year, 1 month ago)

US9155730 BRISTOL MYERS SQUIBB Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent
May, 2023

(1 year, 1 month ago)

US9393238 BRISTOL MYERS SQUIBB Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent
May, 2023

(1 year, 1 month ago)

US7468363 BRISTOL MYERS SQUIBB Methods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
Oct, 2023

(8 months ago)

US8492406 BRISTOL MYERS SQUIBB Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione
Oct, 2023

(8 months ago)

US7968569 BRISTOL MYERS SQUIBB Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
Oct, 2023

(8 months ago)

US8741929 BRISTOL MYERS SQUIBB Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas
Mar, 2028

(3 years from now)

Revlimid is owned by Bristol Myers Squibb.

Revlimid contains Lenalidomide.

Revlimid has a total of 32 drug patents out of which 29 drug patents have expired.

Expired drug patents of Revlimid are:

  • US6281230
  • US6555554
  • US8288415
  • US7119106
  • US8589188
  • US6908432
  • US6045501
  • US8204763
  • US6561976
  • US5635517
  • US6561977
  • US6315720
  • US8315886
  • US6755784
  • US8626531
  • US8404717
  • US7189740
  • US9056120
  • US9101622
  • US9101621
  • US8648095
  • US8530498
  • US9155730
  • US9393238
  • US7468363
  • US8492406
  • US7968569
  • US8288415
  • US5635517

Revlimid was authorised for market use on 21 December, 2011.

Revlimid is available in capsule;oral dosage forms.

Revlimid can be used as use of revlimid (lenalidomide) while preventing the exposure of a fetus or other contraindicated individual to revlimid (lenalidomide), use of revlimid (lenalidomide) to inhibit the secretion of pro-inflammatory cytokines, including tumor necrosis factor alpha, use of revlimid (lenalidomide) for treatment of patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities, use of revlimid (lenalidomide) for the treatment of mantle cell lymphoma (mcl), treatment of male patient having a disease or condition responsive to a teratogenic drug, use of revlimid (lenalidomide) for the treatment of multiple myeloma and transfusion-dependent anemia in myelodysplastic syndromes (mds), use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, in combination with dexamethasone, wherein those patients have not received previous treatment for multiple myeloma, use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, as maintenance following autologous hematopoietic stem cell transplantation (auto-hsct), use of revlimid (lenalidomide) for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib, use of revlimid (lenalidomide) for the treatment of previously treated follicular lymphoma in combination with a rituximab product, use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, in combination with dexamethasone, use of revlimid (lenalidomide) for the treatment of multiple myeloma, use of revlimid (lenalidomide) for the treatment of transfusion-dependent anemia in myelodysplastic syndromes (mds).

The generics of Revlimid are possible to be released after 08 March, 2028.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-131) Feb 22, 2024
Orphan Drug Exclusivity(ODE-241) May 28, 2026
Orphan Drug Exclusivity(ODE-245) May 28, 2026
New Indication(I-706) Feb 17, 2018
New Indication(I-796) May 28, 2022
New Indication(I-797) May 28, 2022
Orphan Drug Exclusivity(ODE-49) Jun 05, 2020
Orphan Drug Exclusivity(ODE-88) Feb 17, 2022
New Indication(I-672) Jun 05, 2016
Orphan Drug Exclusivity(ODE) Jun 05, 2020
New Strength(NS) Jun 05, 2016

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using LENALIDOMIDE ingredient

Market Authorisation Date: 21 December, 2011

Treatment: Use of revlimid (lenalidomide) for the treatment of multiple myeloma and transfusion-dependent anemia in myelodysplastic syndromes (mds); Use of revlimid (lenalidomide) to inhibit the secretion of pro...

Dosage: CAPSULE;ORAL

How can I launch a generic of REVLIMID before it's drug patent expiration?
More Information on Dosage

REVLIMID family patents

Family Patents